Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Capital Expenditures: 2017-2024

Historic Capital Expenditures for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to $204,000.

  • Solid Biosciences' Capital Expenditures rose 126.67% to $204,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $654,000, marking a year-over-year decrease of 56.83%. This contributed to the annual value of $654,000 for FY2024, which is 56.83% down from last year.
  • According to the latest figures from Q4 2024, Solid Biosciences' Capital Expenditures is $204,000, which was up 1,260.00% from $15,000 recorded in Q3 2024.
  • Solid Biosciences' 5-year Capital Expenditures high stood at $1.1 million for Q2 2022, and its period low was $15,000 during Q3 2024.
  • Its 3-year average for Capital Expenditures is $432,000, with a median of $334,500 in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 1,000.00% in 2021, then slumped by 96.08% in 2024.
  • Quarterly analysis of 5 years shows Solid Biosciences' Capital Expenditures stood at $60,000 in 2020, then soared by 1,000.00% to $660,000 in 2021, then increased by 29.70% to $856,000 in 2022, then plummeted by 89.49% to $90,000 in 2023, then spiked by 126.67% to $204,000 in 2024.
  • Its Capital Expenditures stands at $204,000 for Q4 2024, versus $15,000 for Q3 2024 and $286,000 for Q2 2024.